Dr David Spigel speaks to ecancer at ASCO 2024 about the results from ADRIATIC - a study into durvalumab as consolidation treatment for patients with limited-stage small-cell lung cancer.

730 patients were randomised, including 264 to durvalumab and 266 to placebo.

Durvalumab as consolidation treatment after concurrent platinum-based chemoradiotherapy demonstrated a statistically significant and clinically meaningful improvement in overall survival and progression-free survival compared with placebo.